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Background. Few data are reported in the literature about the outcome of patients with severe extended-spectrum β-lactamase-
producing Enterobacterales (ESBL-E) infections treated with ceftolozane/tazobactam (C/T), in empiric or definitive therapy.
Methods. A multicenter retrospective study was performed in Italy (June 2016–June 2019). Successful clinical outcome was 
defined as complete resolution of clinical signs/symptoms related to ESBL-E infection and lack of microbiological evidence of infec-
tion. The primary end point was to identify predictors of clinical failure of C/T therapy.
Results. C/T treatment was documented in 153 patients: pneumonia was the most common diagnosis (n = 46, 30%), followed by 
34 cases of complicated urinary tract infections (22.2%). Septic shock was observed in 42 (27.5%) patients. C/T was used as empiric 
therapy in 46 (30%) patients and as monotherapy in 127 (83%) patients. Favorable clinical outcome was observed in 128 (83.7%) 
patients; 25 patients were considered to have failed C/T therapy. Overall, 30-day mortality was reported for 15 (9.8%) patients. At 
multivariate analysis, Charlson comorbidity index >4 (odds ratio [OR], 2.3; 95% confidence interval [CI], 1.9–3.5; P = .02), septic 
shock (OR, 6.2; 95% CI, 3.8–7.9; P < .001), and continuous renal replacement therapy (OR, 3.1; 95% CI, 1.9–5.3; P = .001) were inde-
pendently associated with clinical failure, whereas empiric therapy displaying in vitro activity (OR, 0.12; 95% CI, 0.01–0.34; P < .001) 
and adequate source control of infection (OR, 0.42; 95% CI, 0.14–0.55; P < .001) were associated with clinical success.
Conclusions. Data show that C/T could be a valid option in empiric and/or targeted therapy in patients with severe infections 
caused by ESBL-producing Enterobacterales. Clinicians should be aware of the risk of clinical failure with standard-dose C/T therapy 
in septic patients receiving CRRT.
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The incidence of severe infections caused by extended-
spectrum β-lactamase (ESBL)–producing Enterobacterales (E) 
is a rising concern worldwide, owing to the successful dissemi-
nation of these species in both the community and health care–
associated ecosystem [1–3]. This situation has led to a dramatic 
increase in the use of carbapenems in high-prevalence coun-
tries, which is suspected to contribute to the ongoing pandemic 
of carbapenemase-producing Enterobacterales. Therefore, alter-
native treatment options and carbapenem-sparing regimens for 
patients with serious infections caused by ESBL-E are urgently 
needed [4].
Ceftolozane/tazobactam (C/T) is a novel β-lactam/β-
lactamase inhibitor (BLBLI) combination that has shown 
potent activity against gram-negative bacteria [5]. It is the com-
bination of a novel cephalosporin, structurally like ceftazidime, 
with a well-known β-lactamase inhibitor. Similar to ceftazidime 
and other expanded-spectrum cephalosporins, ceftolozane is 
not stable when combined with ESBL. For this reason, a formu-
lation for clinical use has been developed in combination with 
tazobactam, a mechanism-based β-lactamase inhibitor that ex-
tends the activity of ceftolozane against many ESBL-E [6].
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Pivotal clinical trials of C/T have demonstrated its effi-
cacy and safety for the treatment of ESBL infections [7, 8] 
and clinical experiences with C/T are accumulating and ex-
panding. However, these studies are almost completely focused 
on treatment of Pseudomonas aeruginosa infections [9–11]. 
Information regarding its real-life use, efficacy, and tolerability 
against ESBL-E in daily clinical practice is limited. Here we re-
port a clinical multicenter experience with C/T to treat serious 
infections due to ESBL-E since its approval in Italy.
METHODS
Study Setting and Design
This was a multicenter retrospective study in which we in-
cluded all adult patients treated with C/T (for at least 96 hours) 
for any confirmed infection produced by ESBL-producing 
Enterobacterales between June 2016 and June 2019 (36-month 
period) in 12 hospitals in Italy. The Internal Review Board of 
Medical Area (DAME) of the coordinating center (Azienda 
Ospedaliera Universitaria Integrata di Udine, Udine, Italy) ap-
proved this study. Because of its retrospective nature, informed 
consent was considered unnecessary.
Cases were eligible for the cohort study if the patient (i) was 
aged ≥18 years, (ii) received ≥96 hours of C/T (with or without 
other antibiotics), and (iii) had a culture-confirmed ESBL-E 
infection.
Data Collection
Patients’ medical records were retrospectively reviewed, and 
data were collected using a pre-established form. The following 
data were recorded: age and sex, underlying diseases according 
to Charlson comorbidity index, type of infection, presence of 
sepsis or septic shock at the time of the infection, suscepti-
bility pattern of ESBL-E isolates, date of start and end of C/T 
therapy, source control of infection, when applicable, other 
antibiotics administered before, concomitant to, and after C/T 
therapy, reasons for C/T use, dosage(s) of C/T and length of 
therapy, adverse events (AEs), clinical outcome, and recurrence 
of infection.
Definitions
Chronic renal disease was defined as the need for hemodial-
ysis or the presence of renal impairment (serum creatinine 
>1.5 mg/dL) at the time of hospital admission. Diagnosis and 
classification of infections were defined according to the cri-
teria of the US Centers for Disease Control and Prevention 
(CDC) [12]. Sepsis and septic shock were defined according 
to standard international criteria [13]. Source control of infec-
tion was considered adequate when any additional measures 
were taken to control the focus of the infection in the 48 hours 
after infection onset (ie, removal of urinary catheter or intra-
vascular catheter, as well as surgical or radiological drainage of 
collection).
An infection was considered “life-threatening” when a patient 
(i) received C/T as rescue therapy because of clinical failure of 
a previous antibiotic regimen, (ii) had septic shock at the time 
of ESBL-E infection, or (iii) required intensive care unit (ICU) 
admission at the time of ESBL-E infection. Recurrence was con-
sidered to have occurred if the infection reappeared after antibi-
otic discontinuation.
Antibiotic Therapy
Indications for C/T and dosage, type of infusion, and dura-
tion were established by infectious diseases specialists in each 
participating center, based on knowledge of previous coloniza-
tion, clinical presentation, and local guidelines. C/T was dosed 
either as approved by the US Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA) as an intra-
venous (i.v.) dose of 1.5 g every 8 h (q8h; standard dosage) or 
as supported by recent data in patients with nosocomial pneu-
monia [14] as an i.v. dose of 3 g q8h (off-label dosage at time 
of treatment); moreover, dosages were adjusted according to 
creatinine clearance. Dose adjustment was required only for 
patients with moderate renal dysfunction (creatinine clear-
ance < 50 mL/min). In patients receiving continuous renal re-
placement therapy (CRRT), C/T was administered at 1.5 g q8h, 
as suggested by pharmacokinetic studies [15, 16]. AEs were 
classified according to World Health Organization (WHO) def-
initions [17].
Depending on the number of drugs used, treatment regi-
mens were classified either as monotherapy or combination 
therapy. Initial antibiotic therapy, defined as empirical anti-
microbial chemotherapy implemented within 24 hours after the 
onset of infection, was assessed, along with definitive antibiotic 
therapy, defined as antimicrobial treatment based on in vitro 
ESBL-E isolate susceptibilities. Drugs in definitive therapy must 
have been administered for at least 50% of the total duration 
of therapy (except for patients who died while on definitive 
therapy, who were included if they received at least 1 complete 
day of therapy). Time to initial definitive therapy was the period 
between the infection onset and initial definitive therapy.
Definition of Patient Outcome
Patient outcome was assessed as success or failure at the end of 
the follow-up period, which finished at the end of August 2019. 
A successful clinical outcome was defined as complete resolu-
tion of clinical signs and symptoms related to ESBL-E infec-
tion and lack of microbiological evidence of infection. Clinical 
failure was defined as either lack of clinical response and/or 
recurrence and/or attributable mortality due to ESBL-E infec-
tion. Specifically, clinical failure was defined as a composite 
of the following: (i) 30-day mortality; (ii) ongoing fever after 
5 days of therapy; (iii) persistence of leukocytosis after 5 days 
of therapy; (iv) presence, after 5  days of therapy, of clinical 
signs of infection that could not be attributed to causes other 
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than ESBL-E infection. Clinical success was defined also as ab-
sence of clinical failure.
Microbiological Methods
All ESBL-E isolates were processed at each participating center 
according to their own practice. In all cases, antibiotic suscep-
tibility was determined by the Vitek 2 (Biomerieux, France) 
automatic method. ESBL-producing strains were phenotypi-
cally identified from baseline specimens using the following 
criteria: minimum inhibitory concentration (MIC) >1  mg/L 
for a third-generation cephalosporin (ceftazidime and/or 
cefotaxime or ceftriaxone); phenotypic ESBL confirmation for 
Enterobacterales in which chromosomal AmpC is uncommon 
(E. coli, Klebsiella spp., Proteus spp.) with an MIC decrease of 
>3 dilutions when combined with clavulanic acid; phenotypic 
ESBL confirmation for Enterobacterales in which chromosomal 
AmpC β-lactamase is common (Enterobacter spp., Citrobacter 
spp., Serratia spp., Providencia spp.) using an MIC of cefepime 
with a decrease of >3 dilutions when cefepime is combined with 
clavulanic acid. However, ESBL detection in each center was 
confirmed as previously reported [18].
Susceptibility of bacteria to C/T was determined by the Etest 
(Liofilmchem, Roseto degli Abruzzi, Italy), and the results 
were interpreted according to the breakpoints proposed by the 
European Committee on Antimicrobial Susceptibility Testing 
(EUCAST) [19].
Statistical Analysis
The primary end point was to identify predictors of clinical 
failure of C/T therapy.
Continuous variables were compared using the Student t test 
and Mann-Whitney U test for normally and non–normally dis-
tributed variables, respectively. The χ 2 test or Fisher exact test 
was used to compare categorical variables. All pretreatment 
variables identified during univariate analysis were tested using 
logistic regression analysis to identify risk factors associated 
with clinical failure. In a multivariate analysis, the model was 
tested using a backward stepwise selection and P <  .05 for all 
variables in order to determine the effects of all anamnestic, 
clinical, and therapeutic variables on clinical success or failure 
of C/T therapy. Empiric and definitive therapy were adjusted for 
confounders (definitive and empiric regimens, respectively). All 
tests of statistical significance were 2-tailed. Differences were 
considered statistically significant at a P value of <.05. Statistical 
analysis was performed with the software package PASW 
Statistics, version 20.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
A total of 153 patients were included during the study period, 
with a median number (interquartile range [IQR]) of 10 (2–28) 
enrolled cases among 12 centers. The baseline characteristics of 
study population are shown in Table 1. Overall, the median age 
Table 1. Baseline Demographics and Clinical Characteristics of 153 
Patients Included in the Efficacy Population Analysis
Variable n = 153 (%)a
Age, median (IQR), y 69 (48–77)
Male sex 82 (53.6)
Community-acquired infection 10 (6.5)
Hospital-acquired infection 143 (93.5)
Ward
 Medical 98 (64)
 Surgical 25 (16.4)
 ICU 30 (19.6)
 Charlson comorbidity index, mean ± SD 4.9 ± 3.6
Underlying diseases
 Cardiac disease 56 (36.6)
 Neurological disease 53 (34.6)
 Chronic renal disease 51 (33.3)
 Diabetes mellitus 42 (27.4)
 Gastrointestinal disease 41 (26.7)
 Solid-organ tumor 37 (24.1)
 Solid-organ transplant 19 (12.4)
 Hematological malignancy 20 (13)
 COPD 35 (22.8)
 Liver disease 22 (14.3)
Other predisposing conditionsb
 Corticosteroids 52 (33.9)
 Other immunosuppressive therapy 29 (18.9)
 Chemotherapy 17 (11.1)
 Neutropeniac 15 (9.8)
Invasive procedures
 Central venous catheter 76 (49.7)
 Urinary catheter 111 (72.5)
 Previous surgeryb 58 (37.9)
 Mechanical ventilation/NIV 28 (18.3)
 Percutaneous endoscopic gastrostomy 2 (1.3)
 Intermittent hemodialysis 25 (16.3)
 CRRT 18 (11.7)
 Previous ESBL-E colonizationb 50 (32.6)
Severity of clinical presentation
 No sepsis 52 (33.9)
 Sepsis 59 (38.6)
 Septic shock 42 (27.5)
ICU admission due to ESBL-E infection 74 (48.3)
Type of infection
 Nosocomial pneumoniae 46 (30)
 ABSSSI 25 (16.3)
 cUTI 34 (22.2)
 cIAI 25 (16.3)
 Bone infection 5 (3.2)
 Primary bacteremia 16 (10.4)
 Other infectionsd 2 (1.3)
Concomitant ESBL-E bacteremia 47 (30.7)
Life-threatening infection 91 (59.4)
Polymicrobial infection 31 (20.2)
Antibiotics before C/T treatment
 Received antibiotics before C/T for current infection 52 (33.9)
 No. of antibiotics received, median (range) 1 (1–3)
 Days of antibiotic therapy, median (range) 6 (3–14)
C/T treatment
 Empiric treatment 46 (30)
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(IQR) was 69 (48–77) years, 82 (53.6%) patients were male, and 
the mean ± SD Charlson comorbidity index score was 4.9 ± 3.6. 
The most frequent source of infection was hospital-acquired 
pneumonia (HAP) in 46 patients (30%, including 20 patients 
with ventilator-associated pneumonia), followed by compli-
cated urinary tract infections (cUTIs; 22.2% of cases, 34/153), 
acute bacterial skin and skin structure infections (ABSSSIs; 
16.3%), and complicated intra-abdominal infections (cIAIs; 
16.3%, 25/153 each). Concomitant bloodstream infection was 
confirmed in 30.7% (47/153 patients).
The etiology of infection and antimicrobial susceptibility pat-
tern of ESBL-E isolates are reported in Table 2. Escherichia coli 
was the most frequently isolated pathogen (48.3%), followed by 
Klebsiella pneumoniae (29.4%) and Enterobacter spp. (14.4%).
At the time of infection, 42 (27.5%) patients presented with 
septic shock and 91 (59.4%) patients were classified as having a 
life-threating infection. Overall, source control of infection was 
considered necessary in 57 patients (37.2%), and in 47/57 cases 
(82.4%) it was considered adequate.
In most patients, C/T was administered once in vitro sus-
ceptibility was confirmed (70%, 107/153), and the median time 
from infection onset to C/T administration (IQR) was 6 (3–15) 
days; C/T doses were 1.5 g q8h (or adjusted according to cre-
atinine clearance) in 115 patients (75%) and 3 g q8h in 38 pa-
tients (25%). Eighty-three percent of the patients received C/T 
as monotherapy in definitive therapy; in 26 (16.9%) patients, 
it was used as combination definitive therapy. No statistically 
significant differences were reported in the use of C/T in mono 
or combo definitive therapy with regards to clinical failure 
(P = .34). Overall, C/T was administered for a median duration 
(IQR) of 14 (8–25) days.
When used as second-line or later, the most common reasons 
for discontinuation of previous antibiotics were in vitro resist-
ance of strains (69.1%) and clinical failure of previous therapy 
(30.9%). Piperacillin-tazobactam was the first-line therapy in 
35% of patients, followed by cephalosporins (44%) and quin-
olones (12%). The median follow-up period of the study popu-
lation (IQR) was 19 (6–49) days.
Overall, 128 (83.6%) patients experienced a successful clin-
ical outcome. Clinical failure was reported in 25 patients: Lack 
of clinical response was recorded in 4 (16%) patients, recur-
rence of ESBL-E infection in 6 (24%), and attributable mortality 
in 15 (60%). Figure 1 stratifies the clinical outcome of patients 
treated with C/T according to the site of infections. Clinical 
success was observed in 88.3% of patients with cUTI, 88% 
with ABSSSI, 87.5% with primary bacteremia, 80% with cIAI 
and bone infections, and 78.3% with hospital-acquired pneu-
monia. Among 54 (35.2%) patients treated with piperacillin-
tazobactam as first-line therapy, clinical failure was reported 
in 11 patients: 5 patients died, and 6 patients showed lack of 
clinical response. According to etiology, a successful clinical 
outcome was reported in 67/74 (90.5%) cases of Escherichia 
coli, 38/45 (84.4%) of Klebsiella pneumoniae, and 15/22 
(68.2%) of Enterobacter spp. infections. All baseline strains 
showed susceptibility to C/T and carbapenems, whereas only 
104 (67.9%) showed susceptibility to piperacillin/tazobactam. 
Despite this, C/T resistance developed during C/T therapy in 
Table 2. Etiology of Infection and Antimicrobial Susceptibility Pattern of 
ESBL-Producing Enterobacterales Isolates
Etiology n = 153 (%)
Escherichia coli 74 (48.3)
Klebsiella pneumoniae 45 (29.4)
Enterobacter spp. 22 (14.4)
Serratia marcescens 5 (3.3)
Proteus spp. 3 (2)
Citrobacter spp. 2 (1.3)
Morganella morganii 2 (1.3)
Antimicrobial Agent No. of Susceptible Strains (%) 
Amikacin 128 (83.6)
Ceftolozane/tazobactam 153 (100)
Ciprofloxacin 74 (48.3)
Colistin 145 (94.7)
Gentamicin 119 (77.7)
Fosfomycin 132 (86.2)
Levofloxacin 88 (57.5)
Meropenem 153 (100)
Piperacillin/tazobactam 104 (67.9)
Imipenem/cilastatin 153 (100)
Abbreviation: ESBL, extended-spectrum β-lactamase.
Variable n = 153 (%)a
 Combination therapy 26 (16.9)
 Time from infection onset to C/T administration, median 
(IQR), d
6 (3–15)
 Days of treatment, median (range) 14 (8–25)
 Extended infusion 34 (22.2)
 Continuous infusion 11 (7.2)
 Intermittent infusion 108 (70.6)
 Standard dosage (or adjusted according to creatinine 
clearance)f
115 (75)
 Off-label dosage 38 (25)
 Adequate source control of infection 47/57 (82.4)
Successful clinical outcome 128 (83.7)
30-d mortality 15 (9.8)
Abbreviations: ABSSSI, acute bacterial skin and skin-structure infection; C/T, ceftolozane/
tazobactam; cIAI, complicated intra-abdominal infection; COPD, chronic obstructive pulmo-
nary disease; CRRT, continuous renal replacement therapy; cUTI, complicated urinary tract 
infection; ICU, intensive care unit; ICU, intensive care unit; IQR, interquartile range; NIV, 
noninvasive ventilation.
aData are presented as No. (%) unless otherwise stated.
bWithin the previous 30 days.
cAbsolute neutrophil count <500/mm3.
dOther infections include central venous catheter–related bacteremia (n  =  1) and 
community-acquired pneumonia (n = 1).
eThirty-two patients with hospital-acquired pneumonia and 14 with ventilator-associated 
pneumonia.
fSix patients with augmented renal clearance.
Table 1. Continued
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3 patients (1.9%), none of whom had a fatal outcome: 1 pa-
tient with HAP (duration of C/T therapy 14 days), 1 patient 
with primary bacteremia (duration of C/T therapy 15 days), 
and 1 patient with cIAI (duration of C/T therapy 20 days). All 
these patients were treated with a standard C/T dosage, with 
etiology of infection due to Klebsiella pneumoniae. The MIC 
value pretreatment with C/T was ≤1 µg/mL; postexposure it 
was >32 µg/mL in 2 patients and >8 µg/mL in 1 patient. Of 
6 (3.9%) patients with augmented renal clearance, clinical 
failure was recorded in 2 cases (33.3%).
Comparison of successful clinical outcome in patients re-
ceiving C/T as empiric therapy in comparison with those 
who received C/T as targeted or rescue therapy is reported in 
Figure 2. Clinical success was reported in 100% (46/46 cases) 
of patients treated with empiric therapy, compared with 83.8% 
(68/86 cases) of targeted therapy and 66.7% (14/21 cases) of 
rescue therapy (P < .0001) cases.
In Table 3 is reported univariate analysis of risk factors asso-
ciated with clinical failure of C/T therapy. ICU hospitalization 
at the time of infection (40% vs 15.6%; P = .01), higher mean 
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Figure 1. Comparison of successful clinical outcome in patients receiving ceftolozane/tazobactam in different sites of infection. Abbreviations: ABSSSI, acute bacterial 
skin and skin-structure infection; cIAI, complicated intra-abdominal infection; cUTI, complicated urinary tract infection.
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Figure 2. Comparison of successful clinical outcome in patients receiving ceftolozane/tazobactam (C/T) as empiric therapy in comparison with those who received C/T as 
targeted or rescue therapy.
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Table 3. Univariate Analysis of Risk Factors for Clinical Failure of C/T Therapy Among Patients With Enterobacterales Infection
Variable
Clinical Success  
(n = 128), No. (%)a
Clinical Failure  
(n = 25), No. (%)a P Value
Age, median (IQR), y 69 (48–78) 68 (47–77) .92
Male sex 69 (53.9) 13 (52) 1.0
Community-acquired infection 9 (7) 1 (4) .78
Hospital-acquired infection 119 (92.9) 24 (96) .89
Ward
 Medical 85 (66.4) 13 (52) .17
 Surgical 23 (17.9) 2 (8) .37
 ICU 20 (15.6) 10 (40) .01
 Charlson comorbidity index, mean ± SD 3.6 ± 3 5.4 ± 2.6 <.001
Underlying diseases
 Cardiac disease 46 (35.9) 10 (40) .82
 Neurological disease 46 (35.9) 7 (28) .49
 Chronic renal disease 36 (28.1) 15 (60) <.001
 Diabetes mellitus 35 (27.3) 7 (28) 1.0
 Gastrointestinal disease 35 (27.3) 6 (24) .8
 Solid-organ tumor 28 (21.8) 9 (36) .19
 Solid-organ transplant 14 (10.9) 5 (20) .2
 Hematological malignancy 15 (11.7) 5 (20) .28
 COPD 29 (22.6) 6 (24) 1.0
 Liver disease 18 (14) 4 (16) .92
Other predisposing conditionsb
 Corticosteroids 45 (35.1) 7 (28) .64
 Other immunosuppressive therapy 23 (17.9) 6 (24) .57
 Chemotherapy 14 (10.9) 3 (12) 1.0
 Neutropeniac 14 (10.9) 1 (4) .46
Invasive procedures
 Central venous catheter 58 (45.3) 18 (72) .01
 Urinary catheter 91 (71.1) 20 (80) .46
 Previous surgeryb 48 (37.5) 10 (40) .82
 Mechanical ventilation/NIV 18 (14) 10 (40) .004
 Percutaneous endoscopic gastrostomy 2 (1.5) 0 1.0
 Intermittent hemodialysis 17 (13.2) 8 (32) .03
 CRRT 8 (6.2) 10 (40) <.001
 Previous ESBL-E colonizationb 40 (31.2) 10 (40) .48
Severity of clinical presentation
 No sepsis 52 (40.6) 0 <.001
 Sepsis 54 (42.2) 5 (20) .04
 Septic shock 22 (17.2) 20 (80) <.001
 ICU admission due to ESBL-E infection 62 (48.4) 12 (48) 1.0
Type of infection
 Nosocomial pneumoniae 33 (25.7) 13 (25) 1.0
 ABSSSI 25 (19.5) 0 .01
 cUTI 31 (24.2) 3 (12) .29
 cIAI 19 (14.8) 6 (24) .24
 Bone infection 4 (3.1) 1 (4) 1.0
 Primary bacteremia 14 (10.9) 2 (8) 1.0
 Other infectionsd 2 (1.5) 0 1.0
Concomitant ESBL-E bacteremia 35 (27.3) 12 (48) .05
Life-threatening infection 81 (63.2) 10 (40) .04
Polymicrobial infection 24 (18.7) 7 (28) .28
Antibiotics before C/T treatment
 Received antibiotics before C/T for current infection 35 (27.3) 17 (68) <.001
 No. of antibiotics received, median (range) 1 (1–3) 2 (1–4) .08
 Days of antibiotic therapy, median (range) 6 (3–13) 7 (4–15) .07
C/T treatment
 Empiric treatment 46 (35.9) 0 <.001
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Charlson comorbidity index (5.4 points vs 3.6 points; P < .001), 
chronic renal disease (60% vs 28.1%; P <  .001), need for me-
chanical ventilation or noninvasive ventilation (40% vs 14%; 
P = .004), CRRT (40% vs 6.2%; P < .001), and septic shock (80% 
vs 17.2%; P < .001) were associated with clinical failure of C/T 
therapy. Conversely, receipt of C/T as empiric therapy (35.9% vs 
0%; P < .001) and adequate source control of infection (75.4% 
vs 7.1%; P < .001) were associated with clinical success of C/T 
therapy. A lower time from infection onset to C/T administra-
tion was reported in patients with clinical success (4 vs 7 days; 
P <  .001). Table 4 shows descriptions of patients who experi-
enced clinical failure with C/T therapy.
Finally, in multivariate analysis, Charlson comorbidity index 
>4 (odds ratio [OR], 2.3; 95% confidence interval [CI], 1.9–3.5; 
P  =  .02), septic shock (OR, 6.2; 95% CI, 3.8–7.9; P  <  .001), 
and continuous renal replacement therapy (OR, 3.1; 95% CI, 
1.9–5.3; P =  .001) were independently associated with clinical 
failure, whereas empiric therapy displaying in vitro activity 
(OR, 0.12; 95% CI, 0.01–0.34; P  <  .001) and adequate source 
control of infection (OR, 0.42; 95% CI, 0.14–0.55; P < .001) were 
associated with clinical success (Table 5).
DISCUSSION
This study reports the largest clinical experience with C/T 
therapy for the treatment of serious ESBL-E infection published 
so far. We showed that C/T is an effective drug for treating dif-
ferent types of ESBL-E infections. This analysis also indicated 
that baseline conditions (expressed by a higher Charlson co-
morbidity index score), severity of clinical presentation at the 
time of infection (as demonstrated by the percentage of septic 
patients in the study population), and CRRT are associated with 
a significantly increased risk of clinical failure, whereas empiric 
therapy displaying in vitro activity and adequate source control 
of infection are associated with clinical success. Of importance, 
clinical success was observed in 83.7% of patients; over 65% of 
patients developed sepsis (38.6%) or septic shock (27.5%) at the 
time of infection.
As previously reported in the literature [1–4], severe infections 
caused by ESBL-E are associated with high rates of treatment 
failure and increased mortality, particularly when appropriate 
antimicrobial therapy is delayed. The role of carbapenems, con-
sidered the first choice for the treatment of these infections [20, 
21], was redefined also for the high incidence of carbapenem-
resistant Enterobacterales strains observed in the last few years. 
Attention is now focused on promotion of carbapenem-sparing 
strategies and evaluation of the efficacy of other drugs, like 
BLBLI combinations that remain active against a considerable 
proportion of ESBL-E; however, the role of these drugs is con-
troversial for the treatment of serious infections due to ESBL 
pathogens [22, 23].
In a pooled post hoc analysis including patients from both 
ASPECT-cIAI [8] and ASPECT-cUTI [7] who had an ESBL-E 
in their baseline cultures (150/1346, 11.1%), clinical cure rates 
were 97.4% for C/T (76/78), 82.6% for levofloxacin, and 88.5% 
for meropenem (23/26) [24]. Interestingly, in our population a 
high clinical success rate was also retained in patients who re-
ceived C/T as salvage therapy (76.2%), as well as those with life-
threatening infection (63.2%). Our data are in line with those 
of the recently published paper ASPECT-NP [14], studying pa-
tients with severe intubated pneumonia, which demonstrated a 
microbiological success rate in infections caused by ESBL-E of 
Variable
Clinical Success  
(n = 128), No. (%)a
Clinical Failure  
(n = 25), No. (%)a P Value
 Combination therapy 23 (17.9) 3 (12) .57
 Time from infection onset to C/T administration, median (IQR), d 4 (1–6) 7 (5–14) <.001
 Days of treatment, median (range) 11 (6–22) 17 (7–29) <.001
 Extended infusion 32 (25) 2 (8) .06
 Continuous infusion 9 (7) 2 (8) 1.0
 Intermittent infusion 87 (67.9) 21 (84) .14
 Standard dosage (or adjusted according to creatinine clearance)f 95 (74.2) 20 (80) .62
 Off-label dosage 33 (25.7) 5 (20) .68
Adequate source control of infection 43/57 (75.4) 4/57 (7.1) <.001
Abbreviations: ABSSSI, acute bacterial skin and skin-structure infection; C/T, ceftolozane/tazobactam; cIAI, complicated intra-abdominal infection; COPD, chronic obstructive pulmonary 
disease; CRRT, continuous renal replacement therapy; cUTI, complicated urinary tract infection; ESBL-E, extended-spectrum β-lactamase Enterobacterales; ICU, intensive care unit; IQR, 
interquartile range; NIV, noninvasive ventilation.
aData are No. (%) unless otherwise stated.
bWithin previous 30 days.
cAbsolute neutrophil count <500/mm3.
dOther infections include central venous catheter–related bacteremia (n = 1) and community-acquired pneumonia (n = 1).
eNosocomial pneumonia was divided into 26 patients with hospital-acquired pneumonia and 7 with ventilator-associated pneumonia among patients with clinical success; 6 patients with 
hospital-acquired pneumonia and 7 with ventilator-associated pneumonia among patients with clinical failure.
fAugmented renal clearance was reported in 4 patients with clinical success and 2 patients with clinical failure.
Table 3. Continued
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57% for C/T compared with 61.6% for meropenem in a setting 
of ESBL-E resistant to C/T, for a rate of 38%. This study caused 
EUCAST to increase the breakpoints of C/T from 1  mg/L to 
2 mg/L [25].
These clinical data, in line with the high in vitro activity 
against ESBL producers reported in the literature [5], con-
figure for C/T a possible role (also in empiric therapy) as a 
carbapenem-sparing agent, especially in a geographical area 
with high spread of gram-negative carbapenem-resistant 
strains [6] and in patients with a lower risk of infection caused 
by a carbapenem-resistant strain [26]. Of importance, no clin-
ical failure was reported among patients with C/T adminis-
tered in empiric therapy when compared with patients for 
whom C/T was used in targeted or rescue therapy (P < .001). 
This observation is in line with our data from multivariate 
analysis, which showed that as empiric therapy, C/T displayed 
in vitro activity associated with clinical success in this study 
population. Of interest, according to etiology, a successful 
clinical outcome was reported in a high percentage (90.5%) of 
cases with Escherichia coli infections, while a lower rate of clin-
ical success was observed for those with Klebsiella pneumoniae 
(84.4%) and Enterobacter spp. infections (68.2%), in line with 
previous observations [24].
On this basis, reflecting an unmet need for licensed 
treatment options, C/T is frequently used for off-label in-
dications, and data regarding how C/T performs overall 
in the treatment of severe infections are expanding [11]. 
Recently, a randomized, controlled, double-blind, phase 3 
noninferiority trial (ASPECT-NP) compared C/T (3 g every 
8 hours) with meropenem for treatment of nosocomial 
pneumonia. Of importance, high-dose C/T was efficacious 
and well tolerated for gram-negative nosocomial pneu-
monia in this critically ill population, comprising mechani-
cally ventilated patients [14].
The current study confirms a previous observation on an as-
sociation between clinical failure and receipt of CRRT during 
C/T therapy [12]. Optimal dosing of C/T in patients receiving 
CRRT is an unresolved issue, and no dosing recommenda-
tions are currently available in this specific setting [6]. Previous 
preliminary reports [16,17] have suggested that a standard 
dosage of 1.5  g q8h should ensure appropriate C/T exposure 
for the treatment of pneumonia in patients undergoing CRRT. 
However, considering that all patients with CRRT in the current 
study received a C/T dosage of 1.5 g q8h, we suggest consider-
ation of an increased posology of C/T in these patients or, if 
possible, routine performance of therapeutic drug monitoring.
Finally, no differences in clinical response rates between pa-
tients treated with combination therapy and those treated with 
monotherapy were observed in this study (P =  .34). However, 
the low number of patients receiving combination therapy 
(n = 26) prevents us from drawing further conclusions with re-
gard to the benefit of combination treatment, especially in pa-
tients with high risk of mortality such as those presenting with 
septic shock. Moreover, another interesting finding was the low 
number of observed AEs during treatment. Only 2 patients de-
veloped mild AEs, although threating physicians interrupted 
treatment in both patients. In pivotal clinical trials, gastrointes-
tinal side effects and abnormal liver enzyme increase were also 
the most frequent AEs described [7, 8].
This study has several limitations that should be addressed. 
First, it was an observational, retrospective study; therefore, we 
may not have been able to control for all measured and unmeas-
ured variables that may have had a clinical impact on patient 
evolution. Nevertheless, our series of ESBL-E infections treated 
with C/T is the largest real-life experience ever reported in lit-
erature. Second, C/T was mainly administered as second- or 
third-line therapy, and the role of prior therapy on clinical out-
come is unclear. Third, susceptibility testing was performed at 
each individual center, and we do not have molecular analysis 
to determine the presence of enzymes associated with antibiotic 
resistance in the isolates. Fourth, we did not perform antibiotic 
blood levels, and we cannot exclude that clinical failure in some 
critically ill patients could be related to the higher clearance of 
β-lactams [27–29], considering also lack of information about 
other variables that may influence the outcome, such as circula-
tory management. Finally, no data were recorded on long-term 
survival over 30 days; thus, we cannot provide more consistent 
information on the risk of recurrence of infection and emer-
gence of strains resistant to C/T therapy.
In conclusion, our data showed that C/T could be a valid 
option in empiric and/or targeted therapy in patients with se-
vere infections caused by ESBL-producing Enterobacterales. The 
decision about C/T in empiric therapy was based on clinical 
judgment at participating centers. In our opinion, the reason 
for the use of C/T was based on knowledge of high spread of 
ESBL strains in the geographical area involved in this study, the 
high rate of hospital-acquired infection, and the severity of the 
clinical condition (as expressed by Charlson comorbidity index 
score and/or rate of septic shock). Clinicians should be aware 
of the risk of clinical failure with C/T therapy in septic patients 
receiving CRRT. The results of this study are relevant to phys-
icians who attend patients with a wide variety of diseases and 
severity of illness.
Table 5. Multivariate Analysis of Risk Factors for Clinical Failure of C/T 
Therapy Among Patients With Enterobacterales Infection
Variable OR 95% CI P Value
Charlson comorbidity index >4 2.3 1.9–3.5 .02
Septic shock 6.2 3.8–7.9 <.001
Empiric therapy displaying in vitro activity 0.12 0.01-0-34 <.001
CRRT 3.1 1.9–5.3 .001
Adequate source control of the infection 0.42 0.14–0.55 <.001
Abbreviations: C/T, ceftolozane/tazobactam; CI, confidence interval; CRRT, continuous renal 
replacement therapy; OR, odds ratio.
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